glycopyrrolate and metformin: label evidence and limits

The glycopyrrolate oral-solution label states that coadministration may increase metformin concentrations and toxic effects. It advises monitoring response and possible clinician-directed dose adjustment.

Which products this evidence covers

Glycopyrrolate oral solution, not every glycopyrrolate formulation.

What this finding does and does not establish

The product and route matter. This source comparison does not independently validate CDI’s moderate category.

Supporting label passage

Metformin plasma levels may be elevated with coadministration of glycopyrrolate, increasing metformin’s pharmacologic and toxic effects. Monitor clinical response to metformin with concomitant glycopyrrolate administration; consider a dose reduction of metformin if warranted.

Read the product label on DailyMed. Section: 7 Drug Interactions — Metformin. Compared label version 15, dated 2026-05-14.

How this brief was prepared

This brief uses an AI-assisted source comparison dated 2026-10-16. The label version and supporting passage were checked again on 2026-10-29. Independent clinical review has not been recorded. The comparison does not validate CDI's severity category or determine individual treatment.

Discuss your exact medicines with your pharmacist

Ask whether the cited formulation and route apply to your products and circumstances. Confirm medication decisions with your pharmacist or prescriber before changing treatment.

Check your medication list with CDI.